Etoricoxib

Etoricoxib is a non-steroidal anti-inflammatory drug (NSAID) that exhibits anti-inflammatory, analgesic, antioxidative, anticancer, anti-angiogenic, and chemopreventive activities. Etoricoxib inhibits COX-2, it also increases activity of superoxide dismutase, catalase, glutathione reductase, and glutathione transferase in animal models. Etoricoxib downregulates expression of matrix metalloproteinases 2 and 9 (MMP2/9), COX-2, MPC-1, VEGF, and MIP-1 in vivo. In other animal models, etoricoxib decreases aberrant crypt foci and lesion formation, suppressing colon carcinogenesis.